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Abstract 
Background: In order to influence every day clinical practice professional organisations issue management guide-
lines. Cross-sectional surveys are used to evaluate the implementation of such guidelines. The present survey investi-
gated screening for glucose perturbations in people with coronary artery disease and compared patients with known 
and newly detected type 2 diabetes with those without diabetes in terms of their life-style and pharmacological risk 
factor management in relation to contemporary European guidelines.
Methods: A total of 6187 patients (18–80 years) with coronary artery disease and known glycaemic status based 
on a self reported history of diabetes (previously known diabetes) or the results of an oral glucose tolerance test 
and HbA1c (no diabetes or newly diagnosed diabetes) were investigated in EUROASPIRE IV including patients in 24 
European countries 2012–2013. The patients were interviewed and investigated in order to enable a comparison 
between their actual risk factor control with that recommended in current European management guidelines and the 
outcome in previously conducted surveys.
Results: A total of 2846 (46 %) patients had no diabetes, 1158 (19 %) newly diagnosed diabetes and 2183 (35 %) 
previously known diabetes. The combined use of all four cardioprotective drugs in these groups was 53, 55 and 60 %, 
respectively. A blood pressure target of <140/90 mmHg was achieved in 68, 61, 54 % and a LDL-cholesterol target of 
<1.8 mmol/L in 16, 18 and 28 %. Patients with newly diagnosed and previously known diabetes reached an HbA1c 
<7.0 % (53 mmol/mol) in 95 and 53 % and 11 % of those with previously known diabetes had an HbA1c >9.0 % 
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Background
The backbone of clinical practice should be evidence 
derived from research and not least prospective, ran-
domised, controlled clinical trials. An important tool for 
distributing contemporary knowledge is guidelines writ-
ten by experts in various fields of medicine. The manage-
ment of patients with coronary artery disease has since 
long been the subject of such guidelines.
One third of patients with coronary artery disease 
have diabetes, a rapidly growing disease globally [1–3]. 
Patients with both diagnoses have a considerably higher 
mortality than coronary patients without diabetes [4, 5]. 
A comprehensive, target driven lifestyle and pharma-
cological strategy improve their prognosis to be almost 
similar to that of patients without diabetes [6, 7]. Still 
preventive management of cardiovascular patients, 
especially those with diabetes, remains inadequate 
[6–8].
The European Society of Cardiology has issued guide-
lines on cardiovascular prevention in clinical practice 
since 1994 with the aim to improve the practice of pre-
ventive cardiology. The EUROASPIRE (European Action 
on Secondary and Primary Prevention by Intervention to 
Reduce Events) cross sectional surveys have since 1995, 
evaluated the implementation of these guidelines [9]. A 
similar survey, the EuroHeart Survey on Diabetes and the 
Heart [7] focused on patients with diabetes. Educational 
activities and updates of guidelines have been based on 
the outcome of these surveys with the intention to fur-
ther improve every day practice. A follow up of the out-
come of these efforts is important to provide feed back 
on aspects of cardiovascular prevention in need of fur-
ther refinement.
The aim of the present investigation was to study 
screening for glucose perturbations in people with coro-
nary artery disease and to compare life-style and pharma-
cological risk factor management in patients with known 
and newly detected type 2 diabetes with those without 
diabetes in relation to European Guidelines on preven-
tion and the management of diabetes and its prestates 
issued in 2007, 2012 and 2013 [9–11].
Methods
EUROASPIRE IV was conducted at 79 centres in 24 
European countries during May 2012 to April 2013 [12]. 
Men and women aged ≥18 to <80 years were identified 
by the following diagnoses of first or recurrent coronary 
artery disease at a time 6–36  months prior to the pre-
sent investigation: (1) coronary artery bypass grafting 
(CABG), (2) percutaneous coronary intervention (PCI), 
(3) acute myocardial infarction (AMI), and (4) acute 
myocardial ischemia.
Information on personal and demographic details, self 
reported lifestyle and medication were obtained during 
an outpatient visit at the participating centres. Data col-
lectors were trained to use standardized methodologies 
for physical measurements.
The following variables were recorded:
Height and weight were measured in light indoor 
clothes without shoes (scales 701 and measuring stick 
model 220; SECA Medical Measuring Systems and 
Scales, Birmingham, UK).
Waist circumference was measured using a metal tape 
applied horizontally at the point midway in the mid-axil-
lary line between the lowest rim of the rib cage and the 
tip of the hip bone (superior iliac crest) with the patient 
standing [13]. Central obesity was defined as a waist cir-
cumference of ≥88 cm for women and ≥102 cm for men.
Blood pressure was measured twice on the right upper 
arm in the sitting position using an automatic digital 
sphygmomanometer (Omron M6; OMRON Corporation, 
Kyoto, Japan) and the mean was used for the analyses.
Physical activity was assessed by means of the Interna-
tional Physical Activity Questionnaire (IPAQ; IPAQ core 
group, Karolinska Institutet, Stockholm, Sweden).
Smoking at the time of interview was defined as self-
reported smoking, and/or a breath carbon monoxide 
exceeding 10  ppm (Bedfont Scientific, Model Micro+) 
[14].
Blood lipids were measured in the fasting state and 
analysed at the central laboratory (Disease Risk Unit, 
National Institute for Health and Welfare, Helsinki, Fin-
land) on a clinical chemistry analyser (Abbot Architect 
(>75 mmol/mol). Of the patients with diabetes 69 % reported on low physical activity. The proportion of patients par-
ticipating in cardiac rehabilitation programmes was low (≈40 %) and only 27 % of those with diabetes had attended 
diabetes schools. Compared with data from previous surveys the use of cardioprotective drugs had increased and 
more patients were achieving the risk factor treatment targets.
Conclusions: Despite advances in patient management there is further potential to improve both the detection and 
management of patients with diabetes and coronary artery disease.
Keywords: Coronary artery disease, Type 2 diabetes, Secondary prevention, Management, Guideline adherence, 
Blood lipids, Blood pressure, Glycaemic control
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analyzer; Abbott Laboratories, Abbott Park, IL, USA) 
using enzymatic method for measuring total cholesterol.
Glycated haemoglobin A1c (HbA1c) was measured at a 
central laboratory with an immunoturbidimetric method 
(Abbot Architect analyzer; Abbott Laboratories, Abbott 
Park, IL, USA) in fasting venous whole blood sampled in 
an EDTA-tube.
An oral glucose tolerance test (OGTT) was per-
formed using 75 grams of glucose in 200 mL of water 
in the morning after at least 10  h of fasting. Blood 
for fasting plasma glucose (FPG) was drawn before 
intake of glucose with a dip safe from the EDTA-
tube in which the HbA1c was collected. Samples for 
the 2  h post-load glucose (2hPG) measurement was 
drawn from whole venous blood using an EDTA-tube. 
Plasma glucose was analysed locally in all centres 
with a photometric point-of-care technique (Glu-
cose 201, HemoCue®, Ängelholm, Sweden) [15]. The 
HemoCue® method is cholesterol sensitive due to the 
measurement in very small volumes with higher lev-
els of glycaemia at low cholesterol levels; therefore the 
glucose values were corrected for cholesterol accord-
ing to the formula: HemoCue® glucose + 0.22 × (total 
cholesterol − 5). Prior to final data analysis the values 
were converted from whole venous blood to plasma 
applying the formula established by Carstensen et  al. 
[16]: plasma glucose =  0.558 +  0.119 ×  whole blood 
glucose. Proper use of the equipment was assured 
through central training of the data collectors, and 
retrieval of HemoCue®-cuvette storage information 
and validation sheets from a selection of the partici-
pating centres.
The use of four cardioprotective drug therapies consist-
ing of antiplatelet drugs, β-blockade, renin–angioten-
sin–aldosterone–system (RAAS) blockade (including 
angiotensin converting enzyme inhibitors and angioten-
sin receptor blockers) and statins was assessed at the out-
patient visit.
Treatment target attainment was assessed for blood 
pressure, LDL-cholesterol and HbA1c as outlined in 
Table 1.
Information on health care providers including par-
ticipation in educational programmes involving physical 
activity, dietary advice and instructions on medications.
Patient groups
The participants were divided into three groups based on 
their glycaemic state:
No diabetes
No history of diabetes and all three tests FPG, 2hPG and 
HbA1c fulfilling the following criteria: FPG <7.0 mmol/L 
(126 mg/dL) and 2hPG value <11.1 mmol/L (200 mg/dL) 
and HbA1c <48 mmol/mol (<6.5 %; Diabetes Control and 
Complications Trial [DCCT]-standard).
Newly diagnosed diabetes
No history of diabetes and at least one of the three tests 
FPG, HbA1c and 2hPG fulfilling the following crite-
ria: FPG ≥7.0  mmol/L (126  mg/dL) and/or 2hPG value 
≥11.1  mmol/L (200  mg/dL) and/or HbA1c ≥48  mmol/
mol (≥6.5 %; DCCT standard)
Previously known diabetes
A self-reported history of diabetes and/or prescribed glu-
cose lowering drugs.
Data management
Data were collected electronically and submitted online 
to the data management centre (EuroObservational 
Research Program for EUROASPIRE IV, European Heart 
House, Sophia Antipolis, France). Data were checked for 
completeness, internal consistency and accuracy. All data 
were stored under the provisions of the National Data 
Protection Regulations.
Statistical analyses
The distributions of patient characteristics across groups 
(Table 2) were compared according to the Kruskal–Wallis 
test and the Chi square test, respectively. Use of pharma-
cological treatments and healthcare providers consulted 
were statistically compared between groups according to 
Table 1 Treatment targets according to the European Guidelines for Diabetes, Pre-Diabetes and Cardiovascular Disease 
as issued 2007 [10], and updated in 2013 [11] and European Guidelines on Cardiovascular Disease Prevention in clinical 
practice issued 2012 [9]
a Or at least a ≥50 % LDL-cholesterol reduction if this target cannot be reached
 Variable Diabetes 2007 Prevention 2012 Diabetes 2013
Blood pressure (mm Hg) (no diabetes) <140/90 <140/90 <140/90
Blood pressure (mm Hg) (diabetes) <130/80 <140/80 <140/85
LDL-cholesterol mmol/L (mg/dL) (no diabetes and diabetes) <1.8 (<70) <1.8 (<70) <1.8 (<70)a
HbA1c % (mmol/mol) (diabetes) ≤6.5 % (≤48) ≤7.0 % (≤53) ≤7.0 % (≤53)
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multilevel logistic modelling to account for the cluster-
ing of patients within centres [17]. Distributions of blood 
pressures, LDL cholesterol and HbA1c levels in patients 
with diabetes, were compared through multilevel linear 
modelling. All models included age and sex as covari-
ates, A level of alpha <0.05 was a priori chosen to indi-
cate statistical significance. All statistical analyses were 
performed at the Department of Public Health, Ghent 
University, Belgium by means of SAS statistical software 
release 9.3 (SAS Institute Inc., Cary, NC, USA).
Ethics
National Co-ordinators were responsible for obtaining 
Local Research Ethics Committees approvals. Written, 
informed consent was obtained from each participant 
by the investigator by means of a signed declaration. The 
research assistants signed in the Case Record Form to 
confirm that informed consent was obtained and stored 
the original of the signed declaration of consent in the 
patient file.
Results
A total of 16,426 medical records were reviewed in the 
search for study participants and 7998 (49 %) attended the 
interview. The reasons for 8428 non-participants were as 
follows: no response to the invitation letter (35 %), refusal 
to attend for personal reasons (39  %), changing medical 
condition or deceased (16  %), living outside the catch-
ment area (3 %) and miscellaneous (7 %). The median time 
between the index event and the interview was 16 months 
(interquartile range 12–22  months). Full information on 
the glycaemic state was available in 6187 (77 %) of the par-
ticipants who attended the interview out of whom 2846 
(46 %) had no diabetes, 1158 (19 %) had newly diagnosed 
diabetes and 2183 (35  %) had previously known diabe-
tes, the vast majority with type 2 and only 41 with type 
1 diabetes. Clinical characteristics of the patients with 
(n = 6187) and without (n = 1811) known glycaemic state 
at the time of interview are presented in Table 2.
There were small differences between the three groups 
regarding the use of antiplatelet agents (predominantly 
aspirin), β-blockers, RAAS-blockers and statins. A com-
bination of all four cardioprotective drug classes was pre-
scribed to ≤60 % of the patients (Fig. 1).
Glucose lowering treatment
Sixty five per cent of the patients with previously known 
diabetes had been given dietary advice. The most 
Table 2 Patient characteristics of the 6187 included and 1811 excluded patients
Data presented are n (%) if not stated otherwise. In case of missing data the total number of observations is given in below the n (%) information
Variable Diabetes P value (difference 
between groups)
Missing info
n = 1811
No
n = 2846
Newly diagnosed
n = 1158
Previously known
n = 2183
Participants (%) 46 19 35
Age (years)
 Mean (SD) 63 (10.0) 65 (9.2) 65 (8.6) <0.0001 64 (9.6)
 <50 320 (11) 68 (6) 103 (5) 191 (11)
 50–59 714 (25) 263 (23) 451 (21) 492 (27)
 60–69 1026 (36) 437 (38) 900 (41) 622 (34)
 >70 786 (28) 390 (34) 730 (33) 506 (28)
Sex 0.006
 Women 674 (24) 268 (23) 594 (27) 412 (23)
 Men 2172 (76) 890 (77) 1589 (73) 1399 (77)
Smoker 464 (16) 165 (14) 304 (14) 0.04 346 (19)
Body mass index, kg/m 28 (4.2) 29 (4.5) 31(5.0) <0.0001 29 (4.7)
 <25 638 (23) (n = 2841) 164 (14) 239 (11) (n = 2171) 384 (21) (n = 1792)
 25–29.9 1349 (48) (n = 2841) 533 (46) 846 (39) (n = 2171) 818 (46) (n = 1792)
 ≥30 854 (30) (n = 2841) 461 (40)) 1086 (50) (n = 2171) 590 (33) (n = 1792)
Central obesity 1439 (51) (n = 2806) 724 (63) (n = 1146) 1510 (71) (n = 2135) <0.0001 895 (51) (n = 1768)
Low or moderate physical activity 
(IPAQ questionnaire)
1215 (55) (n = 2214) 484 (54) (n = 901) 1079 (69) (n = 1667) <0.0001 754 (57) (n = 1318)
FPG mmol/L [mean (SD)] 6.0 (0.6) 7.3 (0.9) 8.6 (2.9) <0.0001 6.1 (1.7)
2hPG mmol/L [mean (SD)] 7.1 (1.7) 10.1 (3.4) – <0.0001 –
HbA1c mmol/mol [mean (SD)] 5.6 (0.3) 6.0 (0.6) 7.2 (1.4) <0.0001 5.8 (0.7)
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commonly used glucose lowering drugs in patients with 
previously known diabetes were metformin (57  %), 
insulin (27  %), sulfonylurea (25  %) and DPP-4 inhibi-
tor (7  %). The most common combinations of glucose 
lowering drugs were metformin  +  sulfonylurea (15  %), 
metformin  +  insulin (11  %) and metformin  +  DPP-4 
inhibitor (6 %). The vast majority of patients (97 %) in all 
three groups responded that they seldom or never altered 
or missed their medication.
Target achievement
The proportion of patients with no, newly diagnosed and 
previously known diabetes reaching a blood pressure tar-
get of <150/100, <140/90 mmHg (target for patients with 
no diabetes 2012 [9]) and the target of <130/80  mmHg 
(target for patients with diabetes 2007 [10]) is presented 
in Fig.  2a. A blood pressure below 110  mm Hg was 
observed among 5 % of the patients.
The corresponding proportions of the three patient 
categories reaching the LDL-cholesterol target of 
<1.8 mmol/L (target for all patients with established car-
diovascular disease 2007 [10], 2012 [9] and 2013 [11]) 
is presented in Fig.  2b. The LDL-cholesterol exceeded 
3.0 mmol/L in 26, 26 and 17 % of patients with no, newly 
diagnosed and previously known diabetes, respectively. 
Total cholesterol <4.5  mmol/L (target for all patients 
with cardiovascular disease 2007 [10] and 2013 [11]) was 
reached in 59, 59 and 68  %. Patients with newly diag-
nosed and previously known diabetes had HbA1c <7.0 % 
(53 mmol/mol) in 95 and in 53 %, respectively. The pro-
portion of patients with previously known diabetes that 
had an HbA1c >9.0 % (>75 mmol/mol) was 11 %.
Health care providers
An overview of healthcare providers is presented in 
Table 3. Twenty seven per cent of the patients with previ-
ously known diabetes had attended a diabetes clinic.
Discussion
The three main findings in this first survey evaluating 
whether European Guidelines for Diabetes, Prediabetes 
and Cardiovascular Disease in 2007 [10] had an impact 
on the management of such patients are: (1) about one 
fifth of the participants had previously undetected dia-
betes. The failure to screen for diabetes when these 
coronary patients were first seen, 1–2  years before the 
interview, led to a lost opportunity to institute early and 
effective preventive measures in a particularly vulner-
able group of patients; (2) although the combined use of 
four cardioprotective drug classes compares favourably 
with the proportions seen in previous surveys, a consid-
erable proportion of the present patient population still 
does not reach guideline recommended treatment targets 
of blood pressure, blood lipids and of glycaemic control; 
(3) life style adaptation was poor among many patients as 
exemplified by a majority reporting low physical activity 
and in general low participation in cardiac rehabilitation 
programmes and diabetes clinics for those with known 
Fig. 1 Proportion of patients with no, newly diagnosed and known diabetes prescribed the different cardioprotective drugs alone and in combina-
tion. Renin–angiotensin–aldosterone–system (RAAS)-blockers includes angiotensin converting enzyme inhibitors and angiotensin receptor block-
ers. ASA aspirin. All 4 = the combination of aspirin (or other anticoagulants) + a β-blocker + a RAAS-blocker and a statin. *p < 0.0001
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diabetes. It can therefore be stated that even if the 2007 
European guidelines had some impact on patient man-
agement there is still a considerable potential to reduce 
the cardiovascular risk in patients with coronary artery 
disease and diabetes just by adhering to available knowl-
edge as reflected in management guidelines, the most 
recent issued in 2013 [11].
The proportions of patients with newly diagnosed 
(19 %) and previously known diabetes (35 %) were similar 
to those reported in EuroHeart Survey of Diabetes and 
the Heart (14 and 31 %, respectively). Guideline recom-
mendation is to screen systematically for diabetes in all 
coronary patients without self-reported diabetes [11]. 
This recommendation was not followed at the time for 
the index coronary event. In the present cohort a vast 
majority of the patients with newly diagnosed diabetes 
had an HbA1c of <6.5  % (<48  mmol/mol) underlining 
the need for an OGTT if FPG and HbA1c are negative as 
recently reported [18].
Blood pressure control was better compared to 
EUROASPIRE III and best in patients without diabetes. 
The proportions of patients with no diabetes, newly diag-
nosed diabetes and previously known diabetes achiev-
ing a target of <140/90  mm Hg was 52, 49 and 43  % in 
EUROASPIRE III [8] and 68, 61 and 54 % in the present 
survey. Both surveys reflect the difficulties in control-
ling blood pressure in patients with diabetes, who often 
require a combination of several different blood pres-
sure lowering drugs. Even if patients with diabetes had 
the highest use of both RAAS-blockers and β-blockers 
Fig. 2 a Proportion of patients with no, newly diagnosed and known diabetes reaching different blood pressure targets. b Proportion of patients 
with no, newly diagnosed and known diabetes reaching different LDL-cholesterol targets.
Table 3 Health-care provider delivering the care presented as % (n/total n) multiple health-care providers are possible 
explaining that columns add >100 %
a Taking into account clustering of patients within centres and adjusted for age and sex
Health-care provider Diabetes
No Newly diagnosed Previously known P valuea
General practitioner 58 (1662/2845) 62 (717/1158) 65 (1408/2183) 0.07
Cardiologist 67 (1916/2846) 73 (848/1158) 74 (1618/2183) 0.69
Endocrinologist/diabetologist 1 (40/2846) 2 (18/1158) 34 (731/2183) <0.0001
Cardiac specialist nurse 5 (134/2846) 3 (30/1158) 5 (114/2183) 0.001
Cardiac rehabilitation program 43 (1201/2824) 39 (451/1145) 36 (777/2154) <0.0001
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it seems that their antihypertensive therapy needs to be 
strengthened [19]. Insufficient patient compliance may 
have contributed even if a majority of patients denied 
such behaviour. Unfortunately the available information 
does not allow a more detailed analysis of this possibil-
ity. An unexpected, but important, observation is that a 
group of patients had blood pressure levels well below 
guideline recommended targets. This finding should 
induce caution in consideration of the J-shaped curve of 
blood pressure control, with increasing cardiovascular 
events among coronary patients with a blood pressure 
consistently below the recommended level [20].
Of patients with no, newly diagnosed and previously 
known diabetes 12, 11 and 20 % reached a LDL-choles-
terol target of <1.8 mmol/L in EUROASPIRE III [8]. The 
corresponding proportions were 16, 18 and 28  %. Any-
how lipid management could undoubtedly have been 
further improved given that the target of <1.8  mmol/L 
was recommended already 5–6  years before the initia-
tion of the present survey [10]. As demonstrated by the 
Euro Heart Survey on Diabetes and the Heart [6] and the 
STENO 2 trial [21] adequate blood pressure and LDL-
cholesterol control is of critical importance for patients 
with diabetes. From the latter study it emerged that lipid 
control accounted for 73  % of the observed decrease in 
morbidity and mortality while the corresponding impact 
of blood pressure and glucose control was 11 and 13 %, 
respectively [22]. Furthermore, lipid control is important 
not only for macro- but also microvascular complications 
in patients with diabetes [23, 24].
Glycaemic control in patients with previously known 
diabetes was similar to that observed in EUROASPIRE 
III [8, 25]. Considering the risk of micro- and macrovas-
cular complications [26, 27] it is of great concern that 
10  % of patients with known diabetes had an HbA1c 
>9.0 % (75 mmol/mol). It has become apparent from ran-
domised trials that the reduction of macrovascular events 
by glucose-lowering strategies has yet to be proven and 
may only be seen after many years of follow-up [21, 28].
The rationale for not only reporting the total propor-
tion of patients above the presently recommended target 
but also at more elevated levels was to show that large 
proportions have considerably higher cholesterol, blood 
pressure and glucose levels and to verify that the present 
findings were not related to patients being just above the 
recommended target.
There was no difference between EUROASPIRE III 
and IV in how many patients had a cardiologist as their 
health-care provider but the proportion of patients seen 
by a general practitioner was higher as was the propor-
tion of patients with previously known diabetes seen by 
an endocrinologist. This changing pattern of caregiv-
ers may at least explain, to some extent, the improved 
management. On the negative side only 3–5  % of the 
present patient cohort attended nurse led prevention 
programmes and less than one third of patients with dia-
betes had been offered specialist diabetes education.
A likely contributor to the observed improvement is 
the emphasis on the poor prognosis for patients with a 
combination of diabetes and coronary heart disease as 
reflected in the first Joint European Guidelines on dia-
betes, pre-diabetes and cardiovascular diseases issued in 
2007 [10]. In an evaluation of the use of these guidelines 
almost nine out of 10 physicians, mainly general practi-
tioners and internists, had the guidelines at their work 
place, and eight out of 10 were aware of and applied them 
in their daily practice [29].
Diabetes schools and comprehensive cardiovascu-
lar rehabilitation is achievable and efficient and has the 
potential to improve treatment given patient partici-
pation [9, 30]. The under use of such programmes is a 
plausible explanation for the poor control of life-style ori-
ented factors with a high proportion of obesity, low phys-
ical activity in a majority, and an unfortunate 14–16 % of 
the patients still smoking. Moe et al. [31] recently studied 
the impact of physical activity on cardiovascular mortal-
ity in a large cohort of people with and without diabetes 
followed during 24 years. Inactive people with diabetes, 
especially those on medical treatment, had a signifi-
cantly increased mortality risk compared with those who 
reported taking weekly physical exercise of at least 2  h. 
This underlines the seriousness of the present findings 
indicating inertia and neglected efforts to improve life-
style habits not least physical activity.
Strengths and limitations
Participating centres included university teaching hospi-
tals, specialist cardiac centres and some district hospitals. 
Volunteer participation in a survey may indicate a par-
ticular interest in cardiovascular prevention. This bias is 
conservative as the standard of care in participating cen-
tres interested in prevention is likely to be high while care 
of patients in everyday practice is probably worse. The 
average interview rate was rather low, 49 %. Usually non-
participants are more likely to have unhealthy lifestyles 
and the present data, if anything, may overestimate the 
true standard of preventive medicine across Europe. As 
can be seen in Table 2 the patients without full glycaemic 
information were more similar to those with no diabetes, 
which may have led to some overestimation of the pro-
portions of known and newly detected diabetes. The fact 
is unlikely to affect the main conclusions of this survey 
considering the high prevalence of patients with glucose 
perturbations. The centres and countries participating 
in European Heart Survey of Diabetes and the Heart, 
EUROASPIRE III and IV are not the same, which has to 
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be kept in mind when interpreting time trends. For logis-
tic reasons only one sample of FPG, 2hPG and HbA1c 
was collected. A definite diagnosis of diabetes should be 
based on at least two measurements. Finally very few 
patients (n = 41) had type 1 diabetes making meaningful 
comparisons between them and those with type 2 diabe-
tes impossible.
A main strength of EUROASPIRE IV is that data are 
based on interviews and standardized examinations 
rather than data from medical records, and that the 
survey despite a seemingly low participation rate pro-
vides comparative information on preventive care in a 
large cross-sectional European population of well-char-
acterized individuals with coronary artery disease. The 
sample size allowed a statistically robust comparison 
between groups according to their glycaemic state. All 
three tests—FPG, 2hPG and HbA1c—as currently rec-
ommended for the classification of patients into their 
respective glycaemic category, were used thereby avoid-
ing misclassification.
Conclusion
The prevalence of self reported diabetes underestimates 
the true prevalence of diabetes in coronary patients. 
A systematic approach to screen for diabetes in coro-
nary patients is required. Although some of the risk 
factors studied were better controlled than in previous 
surveys, there is still considerable potential to further 
reduce cardiovascular risk through lifestyle and opti-
mised cardioprotective medications in patients with 
diabetes and coronary artery disease through imple-
mentation of knowledge into every day clinical practice. 
This is particularly so for LDL-cholesterol where a large 
majority of patients do not reach the treatment target of 
<1.8  mmol/L but blood pressure and glycaemic control 
also need further refinement.
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